Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 20, 2007

Chromos and Pain Thearapeutics Okay Cell Line Engineering Agreement

  • Chromos Molecular Systems inked a cell line development deal with Pain Therapeutics. It will engineer cell lines specific for the expression of a Mab for Pain Therapeutics using the ACE System.

    Pain Therapeutics has the right to use the cell lines for scale up and manufacture of the Mab, following the cell line engineering phase of the agreement.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »